CD8A and neoplasm: Indeed, Batf3-lineage DCs migrate to the draining lymph node to mediate T cell cross-priming, while another subset remains in the tumor site to produce CXCR3 ligands CXCL9 and CXCL10 (CXCL11 in humans) used to recruit CD8+ effector T cells back to the target tissue (27).